MAQS has advised IRLAB Therapeutics AB.
IRLAB Therapeutics AB has been admitted to trading the Company’s shares of series A on Nasdaq Stockholm Main Market.
IRLAB Therapeutics AB (”IRLAB”) is a Swedish pharmaceutical research and development company that focuses on developing novel treatments in Parkinson’s disease. The company’s most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have completed Phase IIa-studies, intend to treat some of the most difficult symptoms related to Parkinson’s disease.
IRLAB’s shares of series A have been listed on Nasdaq First North Premier Growth Market since February 2017.
MAQS’ team consisted of Dag Fredlund (Picture), Hanna Friberg, Jonas Svahn, Daniel Thorbjörnsson, Eric Ehrencrona and Niklas Eskilsson.
Involved fees earner: Eric Ehrencrona – MAQS Advokatbyrå; Niklas Eskilsson – MAQS Advokatbyrå; Dag Fredlund – MAQS Advokatbyrå; Hanna Friberg – MAQS Advokatbyrå; Jonas Svahn – MAQS Advokatbyrå; Daniel Thorbjörnsson – MAQS Advokatbyrå;
Law Firms: MAQS Advokatbyrå;
Clients: IRLAB Therapeutics AB;